Boehringer Ingelheim is a global research-driven pharmaceutical company with a focus on the development of innovative medicines for people and animals. Central Nervous System (CNS) Diseases is one of Boehringer Ingelheim´s Therapeutic Areas, focusing on investigating maladaptive brain circuitry underlying major untreated neuropsychiatric symptoms. Our goal is to develop effective treatments that can be applied across mental illness, through a better understanding of brain circuitry.